BLOG

Biotech Startup Cerevance Strikes Alzheimer’s Research Deal With Merck

Biotechnology startup Cerevance Inc. could earn more than $1 billion through a collaboration with drugmaker Merck & Co. to research potential treatments for Alzheimer’s disease.